



*JOURNAL OF CHROMATOGRAPHY
LIBRARY - volume 68*

*emerging technologies
in protein and genomic
material analysis*

edited by

G. Marko-Varga and P. Oroszlan

ELSEVIER

JOURNAL OF CHROMATOGRAPHY LIBRARY – volume 68

emerging technologies in protein and genomic material analysis

edited by

György A. Marko-Varga

Department of Analytical Chemistry, Lund University
Lund, Sweden

and

Peter L. Oroszlan

Zeptosens AG
Witterswil, Switzerland

2003



ELSEVIER

Amsterdam – Boston – Heidelberg – London – New York – Oxford – Paris
San Diego – San Francisco – Singapore – Sydney – Tokyo

ELSEVIER SCIENCE B.V.
Sara Burgerhartstraat 25
P.O. Box 211, 1000 AE Amsterdam, The Netherlands

© 2003 Elsevier Science B.V. All rights reserved.

This work is protected under copyright by Elsevier Science, and the following terms and conditions apply to its use:

Photocopying

Single photocopies of single chapters may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.com. You may also complete your request on-line via the Elsevier Science homepage (<http://www.elsevier.com>), by selecting 'Customer Support' and then 'Obtaining Permissions'.

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) (978) 7508400, fax: (+1) (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 207 631 5555; fax: (+44) 207 631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works

Tables of contents may be reproduced for internal circulation, but permission of Elsevier Science is required for external resale or distribution of such material.

Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this work, including any chapter or part of a chapter.

Except as outlined above, no part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier's Science & Technology Rights Department, at the phone, fax and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

First edition 2003

Library of Congress Cataloging in Publication Data

A catalog record from the Library of Congress has been applied for.

British Library Cataloguing in Publication Data

A catalogue record from the British Library has been applied for.

ISBN: 0-444-50964-X

ISBN: 0301-4770 (Series)

© The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
Printed in The Netherlands.

JOURNAL OF CHROMATOGRAPHY LIBRARY – volume 68

*emerging technologies in
protein and genomic
material analysis*

*This book is dedicated to our dearest;
Carina, Krisztina Alice, Christofer, Julia, Marton, Sebastian, Tillie, Zsofia*

Preface

The protein- and gene-expression research areas are developing very rapidly and it is fair to say that analytical chemistry plays a very important role in these developments. New challenges lie ahead, with new discoveries and tools opening up novel dimensions in life-science applications. One could argue that the developments in analytical technology are among the major drivers in the biological sciences of today. Examples include the ground-breaking work on DNA-sequencing using capillary electrophoresis, and mass spectrometers being standard instrumentation in research laboratories throughout the world for protein/DNA sequencing and structure work. The pioneering contribution of mass spectrometry to progress in biological sciences was also highlighted by the December 2002 Nobel prizes that were awarded for the invention of electrospray and laser desorption MS.

In parallel, new discoveries in biology and medicine also set new targets for the scientific community regarding performance of new analytical technologies, systems and methods. Our recognition of the pressing need for advanced technologies to fulfill the requirements of the demanding tasks of functional genomic initiatives is the underlying motivation for all of us working on the cutting edge of bioanalytical technologies. With this book, our intention is to

- compile state-of-the-art knowledge of the field and describe emerging technologies
- provide examples by relevant applications and other case studies
- provide insight into the new frontiers of the field that embrace relevant biological systems
- stimulate young scientists and newcomers to be a part of the ongoing biological revolution, where bioanalytical developments are a cornerstone of these successes

The book is intended to serve as a general reference for researchers and scientists within the bioanalytical field as well as for postgraduate students. Each chapter includes references to the corresponding literature to serve as valuable entry points to anyone wanting to move forward in this field, either as a practitioner or for acquiring state-of-the-art knowledge.

Finally, we would like to express our gratitude to the contributing authors for their time and effort in preparing the chapters. Without the engagement and lively interactions we have had over the last half year to get this project finalized, this book would not have been possible.

GYÖRGY A. MARKO-VARGA AND PETER L. OROSZLAN

List of Contributors

J. Abian

Structural and Biological Mass Spectrometry Unit, Department of Medical Bioanalysis, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas (IIBB-CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 161, 7^a Planta, 08036 Barcelona, Spain

P.E. Andren

Biological Mass Spectrometry Center and Department of Pharmaceutical Biosciences, Uppsala University, SE-75124 Uppsala, Sweden and Amersham Biosciences, Björkgatan 30, SE-75184 Uppsala, Sweden

Y. Arntz

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland

J. Bergquist

Department of Analytical Chemistry, Institute of Chemistry, Uppsala University, P.O. Box 531, SE-751 21 Uppsala, Sweden

P. Bertoncini

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland

M. Carrascal

Structural and Biological Mass Spectrometry Unit, Department of Medical Bioanalysis, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas (IIBB-CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 161, 7^a Planta, 08036 Barcelona, Spain

R.J.E. Derks

Department of Analytical Chemistry and Applied Spectroscopy, Division of Chemistry, Faculty of Sciences, vrije Universiteit amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands

Ch. Gerber

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland and IBM Zurich Research Laboratory, Säumerstrasse 4, CH-8803 Rüschlikon, Switzerland

W. Grange

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland

M. Grønborg

Protein Research Group, Department of Biochemistry and Molecular Biology, Odense University/University of Southern Denmark, Odense, Denmark

A. Guttman

Torrey Mesa Research Institute, San Diego, CA 92121, USA

M. Hegner

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland

A.C. Hogenboom

Department of Analytical Chemistry and Applied Spectroscopy, Division of Chemistry, Faculty of Sciences, vrije Universiteit amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands

S. Husale

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland

H. Irth

Department of Analytical Chemistry and Applied Spectroscopy, Division of Chemistry, Faculty of Sciences, vrije Universiteit amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands

O. Nørregaard Jensen

Protein Research Group, Department of Biochemistry and Molecular Biology, Odense University/University of Southern Denmark, Odense, Denmark

H.P. Lang

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland and IBM Zurich Research Laboratory, Säumerstrasse 4, CH-8803 Rüschlikon, Switzerland

T. Laurell

Department of Electrical Measurements, Lund Institute of Technology, Lund University, P.O. Box 118, S-221 00 Lund, Sweden

G.A. Marko-Varga

Department of Analytical Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden

J. Nilsson

Department of Electrical Measurements, Lund Institute of Technology, Lund University, P.O. Box 118, S-221 00 Lund, Sweden

P.L. Oroszlan

Zeptosens AG, Benkenstrasse 254, CH-4108 Witterswil, Switzerland

A. Palm

Department of Chemistry, Indiana University, Bloomington, IN 47405, USA

M. Palmblad

Division of Ion Physics, Uppsala University, Box 534, SE-751 21 Uppsala, Sweden

K. Sköld

Biological Mass Spectrometry Center and Department of Pharmaceutical Biosciences, Uppsala University, SE-75124 Uppsala, Sweden

P. Svenningsson

Department of Physiology and Pharmacology, Karolinska Institute, SE-17177 Stockholm, Sweden

M. Svensson

Biological Mass Spectrometry Center and Department of Pharmaceutical Biosciences, Uppsala University, SE-75124 Uppsala, Sweden

J. Zhang

Institute of Physics, NCCR Nanoscale Science, University of Basel, Klingelbergstrasse 82, CH-4056 Basel, Switzerland

Contents

Preface	vii
List of Contributors	ix
 Chapter 1 Enabling Bio-analytical Technologies for Protein and Genomic Material Analysis and their Impact on Biology	 1
<i>György A. Marko-Varga and Peter Oroszlan</i>	
1.1. Background	1
1.2. Industrial impact	2
1.3. Proteomics—the new frontier after the human genome	3
1.3.1. Human proteome initiatives	3
1.3.2. Multidimensional liquid chromatography	4
1.3.3. Fast and sensitive protein sequencing by mass spectrometry	5
1.4. Protein chip arrays	6
1.5. DNA/RNA analysis	7
1.5.1. Pharmacogenomics	8
1.6. Miniaturized, micro-scale systems	8
1.6.1. Nano-sciences and nano-scale analytical systems	9
1.7. Concluding remarks	9
1.8. References	10
 Chapter 2 DNA Sequencing: From Capillaries to Microchips	 11
<i>Andras Guttman</i>	
2.1. Introduction	11
2.2. The early days of automated DNA sequencing	12
2.3. The advent of capillary gel electrophoresis	13
2.4. Towards higher throughput: capillary array electrophoresis	14
2.5. The promise of miniaturization: microchips	15
2.6. Dealing with the data: bioinformatics	17
2.7. Conclusions	17
2.8. References	19
 Chapter 3 Phosphoprotein and Phosphoproteome Analysis by Mass Spectrometry	 21
<i>Mads Grønborg and Ole Nørregaard Jensen</i>	
3.1. Introduction	21
3.2. Phosphoprotein analysis: A challenge for mass spectrometry	22

3.3.	Mass spectrometry based phosphatase/kinase assays	25
3.4.	Phosphoprotein and phosphopeptide enrichment strategies.	26
3.5.	Chemical derivatization of phosphopeptides and phosphoproteins	27
3.6.	Selective detection and sequencing of phosphopeptides by tandem mass spectrometry	27
3.7.	Liquid chromatography—tandem mass spectrometry (LC-MS/MS)	29
3.8.	Phosphoproteome analysis by mass spectrometry	30
3.9.	Emerging MS methods for phosphoprotein analysis	31
3.10.	Relative quantitation of phosphorylation site occupancy by stable isotope labeling of proteins	32
3.11.	Conclusion	32
3.12.	Acknowledgements	34
3.13.	References	34

Chapter 4	Quantitative Peptide Determination Using Column-Switching Capillary Chromatography Interfaced with Mass Spectrometry	39
	<i>J. Abian and M. Carrascal</i>	

4.1.	Introduction	39
4.1.1.	Capillary liquid chromatography	40
4.1.2.	Interfacing LC with electrospray MS	42
4.1.3.	Advantages of miniaturization in LC-MS	45
4.1.3.1.	Chromatographic considerations	46
4.1.3.2.	Mass spectrometric considerations	46
4.1.4.	Drawbacks of capillary chromatography	49
4.1.5.	The use of pre-columns and column-switching in CapLC	50
4.1.5.1.	Practical advantages of PC with miniaturized LC-MS systems	51
4.1.6.	Quantitative analysis	52
4.2.	Instrumentation	53
4.2.1.	Commercial and custom-made capLC instrumentation	53
4.2.2.	Capillary column preparation	53
4.2.3.	Pre-columns and column-switching	55
4.2.4.	NanoESI and microESI sprayers and interfaces	55
4.2.4.1.	Voltage application	56
4.2.4.2.	Practical set-up	57
4.3.	Examples of quantitative peptide analysis	58
4.3.1.	Endothelin extraction from HUVEC	58
4.3.2.	Bradykinin extraction from plasma	59
4.3.3.	CapLC columns	59
4.3.4.	Micro-ESI interface	60
4.3.5.	CapLC- μ ESI MS	60
4.3.6.	On-line pre-concentration (PC)-capLC- μ ESI MS	61
4.3.7.	Matrix effects and loading capacity of the PC-capLC system	63
4.3.8.	Roughness and stability of the μ ESI-MS interface	65
4.3.9.	General performance of the analytical system	66
4.4.	Resume	68
4.5.	Acknowledgements	70
4.6.	References	70

Chapter 5	On-line Continuous-flow Multi-protein Biochemical Assays for the Characterization of Bio-active Compounds Using Electrospray Quadrupole Time-of-Flight Mass Spectrometry	75
	<i>R.J.E. Derks, A.C. Hogenboom and H. Irth</i>	
5.1.	Introduction	75
5.2.	Experimental	76
5.2.1.	Chemicals	76
5.2.2.	Continuous-flow set-up	77
5.2.3.	MUX-technology set-up	78
5.2.4.	Batch experiments set-up	78
5.3.	Results and discussion	79
5.3.1.	Optimization of MS conditions: buffers and organic modifier	80
5.3.2.	MS-based bioassay: optimization with the use of batch experiments	80
5.4.	On-line continuous-flow MS-based biochemical interaction	82
5.4.1.	Fluorescein-biotin/streptavidin assay	82
5.4.2.	Digoxin/anti-digoxigenin assay	82
5.4.3.	Parallel biochemical assay	82
5.4.4.	MS and MS-MS switching for identification of (bio-)active compounds in a multi-protein assay	83
5.4.5.	MUX technology	85
5.5.	Conclusions	88
5.6.	References	89
5.7.	Appendix	90
5.7.1	Theory	90
Chapter 6	Capillary Isoelectric Focusing Developments in Protein Analysis	95
	<i>A. Palm</i>	
6.1.	Introduction	95
6.2.	Detection	96
6.2.1.	Imaging CIEF	96
6.2.2.	Other detection methods	98
6.3.	Micropreparative CIEF	103
6.4.	Internal standards	104
6.5.	Capillary coatings	105
6.6.	CIEF applications	106
6.6.1.	Protein complexes	106
6.6.2.	Peptides	107
6.6.3.	Recombinant proteins	107
6.6.4.	Hemoglobin	113
6.6.5.	Microorganisms	114
6.7.	CIEF-mass spectrometry	115
6.8.	Miniaturized CIEF and chip-IEF	122
6.8.1.	Imaging detection	122
6.8.2.	Mobilization strategies	124
6.8.3.	Miscellaneous applications	125
6.8.4.	Mass spectrometry	125
6.8.5.	Natural pH gradients	129
6.9.	References	130

Chapter 7	Bio-affinity Extraction for the Analysis of Cytokines and Proteomics Samples.	135
	<i>György Marko-Varga</i>	
7.1.	Introduction to cytokine analysis.	135
7.2.	Capillary micro extraction linked to MALDI-TOF MS for the analysis of cytokines at femtomole levels.	136
7.3.	Application to the analysis of IL-8 and IL-10 in cell samples	139
7.3.1.	IL-10 Analysis.	140
7.3.2.	Analysis of IL-8	140
7.4.	Cytokine analysis conclusions	146
7.5.	Sample preparation for proteomics studies	147
7.5.1.	Sample preparation of cell lysates	147
7.5.2.	1D-gel analysis utilizing restricted access affinity purification.	148
7.5.3.	2D-gel analysis utilizing restricted access affinity purification.	149
7.6.	Proteomics analysis conclusions	150
7.7.	Acknowledgements	152
7.8.	References	152
Chapter 8	Peptidomics-based Discovery of Endogenous Neuropeptides in the Brain	155
	<i>Per E. Andren, Marcus Svensson, Karl Skold and Per Svenningsson</i>	
8.1.	Introduction to peptidomics	155
8.2.	Peptidomics sample preparation	156
8.3.	Mass spectrometry of brain tissue peptide extracts	157
8.4.	Tandem mass spectrometry of endogenous neuropeptides	158
8.5.	Simultaneous detection and identification of a large number of endogenous neuropeptides	158
8.6.	Identification of novel neuropeptides.	158
8.7.	Identification of 'classical' neuropeptides	159
8.8.	Identification of post-translational modifications of neuropeptides	160
8.9.	Effect of microwave irradiation of brain tissue	165
8.10.	Conclusions	166
8.11.	References	166
Chapter 9	The Beauty of Silicon Micromachined Microstructures Interfaced to MALDI-TOF Mass Spectrometry	169
	<i>Thomas Laurell, Johan Nilsson, György Marko-Varga</i>	
9.1.	Background to miniaturization and microstructure developments within the proteomics research area	169
9.2.	Introduction to microstructure technology	171
9.3.	Basic concepts of protein determination.	172
9.4.	The benefits gained by miniaturization	174
9.4.1.	Silicon microfabrication	175
9.4.2.	Flow-through dispenser fabrication	176
9.4.3.	Dispenser operation	178
9.5.	Interfacing capillary liquid phase separations to MALDI peptide mass fingerprinting	179
9.6.	Integrated on-line protein workstation	182

9.7.	Integrated microanalytical tool-box components	183
9.7.1.	Integrated on-chip microextraction system interfaced to peptide map fingerprinting	184
9.8.	Applications to proteomic samples from high sensitivity determinations	185
9.8.1.	Analyzing targeted disease cells in proteomic studies	188
9.8.2.	On-line tryptic digestion sample preparation using the SMEC-microchip	188
9.9.	In-vial digestion using nanovial MALDI-target arrays	191
9.9.1.	Dispenser-aided nanovial digestion	192
9.9.2.	High speed in-vial protein catalysis	193
9.10.	Compiled platform developments	195
9.11.	Conclusions	195
9.12.	Future perspectives	196
9.13.	References	196

Chapter 10	Identification and Characterization of Peptides and Proteins Using Fourier Transform Ion Cyclotron Resonance Mass Spectrometry	199
	<i>M. Palmblad and J. Bergquist</i>	

10.1.	On DNA and proteins	200
10.2.	On body fluids as sources for clinical markers	203
10.2.1.	Plasma	204
10.2.2.	Cerebrospinal fluid	205
10.2.3.	Saliva	205
10.2.4.	Urine	206
10.3.	On mass spectrometry	206
10.3.1.	Ion cyclotron resonance	207
10.3.2.	Fourier transform spectroscopy	209
10.3.3.	Ionization techniques	210
10.4.	Experimental approaches	212
10.4.1.	Sample purification	213
10.4.2.	Liquid chromatography	214
10.4.3.	Capillary electrophoresis	214
10.4.4.	Electrospray ionization	216
10.4.5.	Mass spectrometry	217
10.4.6.	Mass spectrometry, peptide mass fingerprinting and information	218
10.5.	Proteins in mixtures and human body fluids	221
10.6.	Conclusions	233
10.7.	Acknowledgements	235
10.8.	References	235

Chapter 11	Biological Single Molecule Applications and Advanced Biosensing	241
	<i>M. Hegner, Ch. Gerber, Y. Arntz, J. Zhang, P. Bertoncini, S. Husale, H.P. Lang and W. Grange</i>	

11.1.	Introduction	241
11.1.1.	Macroscopic versus microscopic measurements in biology	241
11.1.2.	Force sensitive methods	241
11.2.	Optical tweezers	243
11.2.1.	Origin of optical forces	243
11.2.2.	Experimental details	244

11.2.2.1.	Calibration procedure	244
11.2.2.2.	State of the art instrumentation	246
11.2.2.3.	Thermal noise	246
11.2.3.	Recent experiments	246
11.2.3.1.	Molecular motors	247
11.2.3.2.	Mechanical properties of single molecules	247
11.3.	Scanning force spectroscopy	248
11.3.1.	Introduction to dynamic force spectroscopy	248
11.3.2.	Theoretical background	249
11.3.3.	Experimental	250
11.3.4.	Probability distribution and specificity of rupture forces	250
11.3.5.	Dynamic measurements	251
11.3.5.1.	Base pair dependence	251
11.3.5.2.	Temperature dependence	252
11.3.6.	Future of dynamic force spectroscopy	253
11.4.	Advanced bio-sensing using micro-mechanical cantilever arrays	254
11.4.1.	Introduction to micro-mechanical bio-sensors	254
11.4.2.	Nanomechanical cantilever as detectors	254
11.4.3.	Overview of the two detection modes	254
11.4.3.1.	Static mode	254
11.4.3.2.	Dynamic mode	255
11.4.4.	Setups	256
11.4.5.	Future applications of cantilever arrays	260
11.5.	Conclusion	261
11.6.	Acknowledgements	262
11.7.	References	262
	Subject Index	265

CHAPTER 1

Enabling Bio-analytical Technologies for Protein and Genomic Material Analysis and their Impact on Biology

GYÖRGY A. MARKO-VARGA^a and PETER L. OROSZLAN^b

^a*Department of Analytical Chemistry, Lund University, Lund, Sweden*

^b*Zeptosens AG, Witterswil, Switzerland*

1.1. BACKGROUND

Although the human genome was made public by the end of June 2000, it was not the complete human map; there were still parts that were not readily available. Currently, there is a plan that the National Human Genome Research Institute will publish the finished draft of the human-genome sequence in a scientific journal by 2003. During the period between the first launch of the human-genome sequences (June 2000) and today, the focus has turned towards the post-genomic area. High capacity and high performance technologies that are able to identify the expression of proteins are currently a research area attracting enormous attention. This is due to the fact that the DNA coding and 'the holy grail' of human life is no further than the nearest computer with an Internet connection. Almost the entire genome can be searched. These gene sequences hold only a limited percentage of the entire proteome that is present in cells. The reason is that, upon transcription and translation, proteins in many cases undergo a post-translational modifying step.

Proteomics has become the new 'hot' research where the protein expression area has received enormous attention scientifically as well as from investors in the stock market [1]. Several hundred million dollars have already been invested by the Pharma and Biotech companies and the business growth until 2005 is expected to be \$5 billion [2].

Academia, the pharmaceutical industry and the biotech sector have moved their efforts and positions towards trying to complete the human proteome and what it holds. It seems that this task is not only a major effort to fulfil, but also difficult to define. What exactly the proteome as such holds in terms of gene products is one aspect of addressing the entire map of the human proteome. The other aspect is that the post-translational modifications that occur within the cell reflect a fundamental and very important process whereby additionally a large number of proteins is present. The post-translationally modified proteins may occur as many variants all sharing a larger degree of protein sequences, e.g. enzymes often occur as

one protein sequence holding an inactive form in a state of rest, which after modification becomes activated. These activation mechanisms include phosphorylations, carbohydrate modifications or simply cleaving a protein sequence from the pre-protein.

Many academic scientists argue that efforts to map the entire proteome are a matter of organisation. This illustrates the need for a single body to coordinate research efforts and advance human knowledge as a whole rather than according to the corporate agenda. Unlike the genome project, where DNA sequencing technology propelled the project towards a single easily understood goal, the proteomics field is driven by an array of emerging technologies having multiple goals. Scientists would like to identify ultimately all human proteins, determine the shapes they assume inside cells and understand their function by observing how they change in different circumstances. The initiative of starting an inventory of protein content in cells was suggested in the 1980s [3].

The Human Proteome Organization (HUPO) is currently trying to provide some help coordinating large proteome investigations. There is also agreement within HUPO that the focus of its work will be on mapping proteins within certain biological materials generated from human clinical studies, with cancer research of primary interest [4].

The 'Human Proteome Index' (HPI) [5] is another initiative from the founders of SwissProt. It is a human protein database to which all human protein sequences can be submitted. Because national and international funding into proteomics research is steadily increasing, sequence information should be stored in a central database accessible to everyone. The number of inactive protein sequences forms one part of the required information. This detailed biological information addresses the actual cell compartment from where the specific protein in question originates and/or where it was found to be present. It is of mandatory importance. An identity by itself, that a protein is expressed, or found to be up- or down-regulated in a certain disease or disease in-vivo or in-vitro model, comprises only the first step in the proteomics process. Unless the expression can be linked to its biological function, resulting limitations in the verification of the biological role will remain.

Sequencing the genome is just the start in a long march towards an understanding of how humans grow and develop and also to the link with disease and disease evolution. Genes are powerful, but ultimately we need to understand the proteins that carry out bodily functions.

In this context, the evolving 'new science' and its various disciplines are expected to have a large impact also on the life science industry.

1.2. INDUSTRIAL IMPACT

State-of-the-art drug discovery and development—the foremost important consumer of new analytical technologies—is driven largely by chemistry and high-throughput screening. Questions about the biological effect of a candidate drug (i.e. toxicity, efficacy) are addressed only at a rather late phase of the development process. In the contemporary pharmaceutical business, much effort is directed to reducing drug development times significantly in order to expedite marketing incentives. A rational time-saving approach could contribute significantly to the short-term (i.e. fast product launch) as well as